Other drugs effectively used in the treatment of IBD, which have the ability to target the immune system response modulation, include Janus Kinases Inhibitors and antibodies that inhibit the migration of leukocytes to the gastrointestinal tract, such as vedolizumab (anti-α4 β7 integrins), abrilumab (anti-α4β7 IgG2), etrolizumab (anti-β7) or sphingosine-1 Phosphate Receptor Modulators. This evidence concerns the gene S1PR1 and inflammatory bowel disease.